OncoPLE™ - Next Generation Tracker for Cancer Cell
As the first killer of human health, conquering cancer is the goal of scientists. Chemotherapy and radiotherapy and other broad-spectrum treatments often lead to lose-lose situation, and specific treatments are increasingly favored. Creative Biolabs has conducted extensive explorations in developing targeted delivery methods for tumors. OncoPLE™ is one of the outstanding representatives.
Background
In general, cancer therapy is mainly divided into two types. One is broad-spectrum therapies like radiotherapy or chemotherapy, and the other is cell-specific therapies, such as the ability to target specific tumor cells that can express a particular protein. The biggest problem with broad-spectrum therapies is that they are capable of killing both cancerous and normal tissues, while targeted therapies are successful in their specificity and are also limited by their specificity. In other words, these therapies may not be effective in patients who are unable to express such target proteins. In addition, tumors may develop new modes to resist such targeted therapies.
OncoPLE™ - Next Generation Tracker for Cancer Cell
Phospholipid ethers (PLEs) are natural molecules that accumulate on the membrane of cancer cells rather than normal cells. This is the basis for the development of OncoPLE™. Compared with normal cells, the metabolism of tumor cells needs to undergo significant changes, which lead to changes in cell membranes, increasing the presence and stability of specific regions which are called lipid rafts on the cell membrane, and the fact that PLEs are expressed only in tumor cells confers its ability to target them. OncoPLE™ is designed to specifically bind to these lipid raft regions on tumor cell membranes. When enough OncoPLE™-drugs are bound to lipid raft, a lipid raft transmembrane flip is initiated to deliver the anti-tumor drug into the cytoplasm of the tumor cell, and then OncoPLE™-drugs will be transported along the Golgi network and aggregated around the mitochondria and endoplasmic reticulum, where they exert the anti-tumor effect.
Fig.1 Schematic diagram of OncoPLE™.
Advantages of OncoPLE™
- Independent of specific cell surface proteins
- Versatile for delivery of various anticancer drugs
For a particular type of cancer, a specific cell surface antigen is not expressed on all cancer cells, so targeting such antigens is difficult to avoid the situations of escaped criminals. Whereas, OncoPLE™ is able to target all cancer cells of a certain cancer type.
Creative Biolabs is a clinical-stage CRO who focuses on the discovery and development of drugs for the treatment of cancer. We not only have a variety of cancer vaccine development strategies but also establish multiple corresponding means to selectively and efficiently deliver tumor vaccines to target sites to further enhance the efficacy of the vaccine. If you are interested in our OncoPLE™ platform, please contact us!
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
